• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      ASH 2021 - The 63rd American Society of Haematology Annual Meeting and Exposition

      About the latest data for VENCLYXTO® in Chronic Lymphocytic Leukaemia (CLL)

      To receive the latest AbbVie information on upcoming congresses such as BSH 2022
      (3-5 April)


      On demand: Access content from ASH 2021

      Dr Toby Eyre and Dr Piers Patten

      Insights from ASH 2021:
      Chronic Lymphocytic Leukaemia

      Dr Piers Patten and Dr Toby Eyre review the findings of CLL-13, CLL-14 and MURANO studies

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-220028. Date of preparation: January 2022.